

CURRICULUM VITAE: DR. SULIMAN ABDALLAH ALSAGABY



Dr. Suliman Alsagaby

Associate Professor
and Consultant
Clinical Scientist
Majmaah University
College of Applied
Medical Sciences
Department of Medical
Laboratories

Mobile phone

+966 (0) 542552749

Email Address

s.alsagaby@mu.edu.sa

Date of Birth

71th Jan 1984

Nationality

Saudi

Languages

Arabic
English

Computer Skills

Microsoft office
Presem-graphpad
Photoshop

Education

2001 - 2005	Qassim University	KSA - Alqassim
	Bachelor degree in Medical laboratories Average grade: 4.22/5	
2005 -2006	King Fahd Specialist Hospital	KSA - Buraydah
	Internship in Medical Laboratory ○ Grade: very good	
2007 - 2008	Colchester English Study Centre	UK - Colchester
	General English courses	
2008 May - Sep	Essex University	UK - Colchester
	English pre-sessional course for academic purposes	
2008 - 2009 Sep	Essex University	UK - Colchester
	MSc degree in Molecular Medicine Thesis title: Molecular Characterization of Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) receptor in human leukemic monocytes ○ Grade: Merit	
2010 - 2013	Cardiff University	UK - Cardiff
	Doctor of Philosophy (PhD) in Molecular Medicine and Haematology/Oncology from School of Medicine. Thesis Title: Proteomics Analysis of Chronic Lymphocytic Leukaemia cells.	
2019 - Present	Certified Consultant Clinical Scientist from Saudi Commission for Health Specialties (SCFHS).	

Molecular Medicine and Haematology/Oncology Related Conferences

(A) Conferences in which I presented my research findings

2009 (1 Day)	Essex University	UK – Colchester
	Title:	Molecular Medicine
	Oral Presentation:	Molecular characterization of the CTLA-4 Expression by Acute Myeloid Leukaemia (AML) Cells
2011 (3 Days)	Welcome Trust	UK – Cambridge
		British Society of Proteomics
	Title:	From Visible to Hidden Proteomics
	Poster Presentation:	Differential Proteome is Associated with CD38 Positive Chronic Lymphocytic Leukaemia (CLL) cells
2012 (4 Days)	Brunel University	UK – London
	Title:	6 th Saudi Scientific International Conference
	Poster Presentation:	Proteomics Based Identification of Differentially Expressed Proteins in Chronic Lymphocytic Leukaemia Cells
2014 (3 Days)	Omics Group	USA – Chicago
	Title:	International Conference of Proteomics and Bioinformatics.
	Poster Presentation:	Proteomics Based Identification of Myosin-9 as a Biomarker of Low-Risk Chronic Lymphocytic Leukaemia (CLL)

2015 (2 Days)	Oxford Global	UK – Manchester
	Title:	10 th Annual Biomarker Congress
	Poster Presentation:	Proteomics-Based Strategies for the Discovery of Biomarkers in Chronic Lymphocytic Leukaemia (CLL)
2015 (1 Day)	Majmaah University	KSA – Alzufli
	Title:	Molecular Medicine
	Oral Presentation:	From Proteomics to the Discovery of Biomarkers and Therapeutic Targets in Cancer
2016 (3 Days)	Sengenics	Brunei
	Title:	Proteomics and Immunomics
	Oral Presentation:	Proteomics of Blood Cancer
2017 (1 Day)	Majmaah University	KSA – Alzufli
	Title:	Cancer Research Day
	Oral Presentation:	Prognosis and Therapy of Blood Cancer: Impact of Transcriptomics, Proteomics and Nano-Particles
2017 (1 Day)	Majmaah University	KSA- Alzufli
	Title:	Asthma Research Day
	Oral Presentation	Immune and Inflammatory Molecules Drive the Progression of Blood Cancer: Possible Link to Asthma

2018 (3 days) **King Faisal Specialist Hospital KSA-Riyadh
and Research Centre**

Title: Proteins analysis using Mass Spectrometry

Oral Presentation: Proteomics Quantitation and Proteomics of Blood Cancer

2019 (2 days) **King Fahad Medical City, KSA-Riyadh
College of Medicine**

Title: Proteomics in Medicine

Oral Presentation: Proteomics for disease biomarkers discovery

B: Conferences that I attended with no poster or oral presentation

2010 (3 Days) **Welcome Trust UK – Cambridge
British Society of Proteomics**

Title: From Qualitative Proteomics to Quantitative Proteomics

2012 (1 day) **SOAS University of London UK – London**

Title: UK CLL Annual Scientific Day

2017 (1 Day) **King Faisal Specialist Hospital KSA-Riyadh
and Research Centre**

Title: Next Generation Sequencing (NGS) for Clinical application in Oncology

Molecular Medicine and Haematology/Oncology Related Workshops/Training

2010 (3 Days)	Cardiff University	UK – Cardiff
	Title:	Proteomics Analysis
2010 (1 Week)	Cardiff University	UK – Cardiff
	Title:	Proteomics and Bioinformatics
2010 (1 Week)	Welcome Trust	UK – Cambridge
	Title:	Advanced Proteomics and Bioinformatics
2011 (1 Day)	Welcome Trust	UK – Cambridge
	Title:	Quantitative Proteomics
2014 (2 Days)	King Fahd Medical City	KSA – Riyadh
	Title:	Flow-Cytometry for Analysis of Blood Malignancies
2015 (3days)	LI-COR Biosciences	Germany – Homburg
	Title:	Protein and DNA Detection and Quantification Using Near Infrared Licor CLX Technology
2017 (1 day)	King Fahd Specialist Hospital	KSA – Buraydah
	Title:	Testing HER2/ERBB2 Gene Using FISH in Breast Cancer and Non Small Cell Lung Cancer
2018 (2 Day)	BD Biosciences	UEA – Dubai
	Title:	Operator Training on Flow-cytometry (BDFACSCanto II) and the acquisition with analysis software BDFACSDiva v8.0.1

2018 (1 Week)	Agilent Technologies	Germany – Waldbronn
	Title:	Genomics Training: Set up, QC and Analysis of Gene Expression Experiments with the Agilent DNA Microarray and Agilent SureScan Platform
2018 (1 Week)	Agilent Technologies	Germany – Waldbronn
	Title:	Advanced Proteomics Acquisition and Data Analysis with Quantification

Job Experience

2006 – 2007	Almohimeed Hospital	KSA – Buraydah
	Position:	Diagnostic Lab Specialist
2007 – 2013	Majmaah University	KSA – Alzulfi
	Position:	Teacher Assistant in the Department of Medical Laboratories
2014 – 2020	Majmaah University	KSA – Majmaah
	Position:	Assistant Professor of Molecular Medicine and Haematology/Oncology in the Department of Medical Laboratories, College of Applied Medical Sciences.
2020 – Present	Majmaah University	KSA – Majmaah
	Position:	Associate Professor of Molecular Medicine and Haematology/Oncology in the Department of Medical

Laboratories, College of Applied
Medical Sciences.

2013 – 2015	Majmaah University	KSA – Alzulfi
	Position:	Vice-Dean of Quality and Development at College of Science
2015 – 2017	Majmaah University	KSA – Alzulfi
	Position:	Vice-Dean of Postgraduate Studies and Scientific Research at College of Science
2013 – 2018	Majmaah University	KSA – Alzulfi
	Position:	Head of Central Biomedical Science Research Labs (CBRLs).
	Played Roles:	Founder of CBRLs Supervisor and operator of the Proteomics Unit, the Transcriptomics Unit and the Flow-cytometry Facility
2013 – Present	Majmaah University	KSA – Alzulfi
	Position:	Leader of the Molecular Cancer Research Group (MCRG)
	Played Roles:	Founder of MCRG Lead the research team to the discovery of cancer biomarkers and therapeutic targets
2013- present	King Khalid Hospital	KSA – Majmmah
	Position:	Consultant Clinical Scientist in the hospital diagnostic lab.

Played roles: consultation services for the lab tests performed for patients.
Participate in training internship students from Majmaah University

Scientific Research Activity

(A) Establishment of Central Biomedical Sciences Research Labs (CBRLs)

In Majmaah University (2014), I was assigned to establish the Central Biomedical Sciences Research Labs (CBRLs). Therefore, I led a group, consisted of three assistant professors, to establishment the CBRLs that includes four main research labs:

- 1- Molecular Biology and Biochemistry lab
- 2- Microbiology lab
- 3- Histopathology lab
- 4- Experimental Medicine (animal) lab

Since the establishment, I have been working as a head of the CBRLs.

(B) Establishment of the Molecular Cancer Research Group (MCRG)

Following the establishment of the CBRLs, I started the MCRG that I have been leading to conduct scientific research in the field of molecular cancer, in particular blood malignancies. The research group is made of five members and our interest has been focused on studying the molecular basis of blood cancer for the discovery of biomarkers and therapeutic targets.

(C) Publications

My papers can be found in the following:

- 1- My account in Googl Scholar:
<https://scholar.google.com/citations?user=HKZq6VMAAAAJ&hl=ar&oi=ao>
- 2- My ORCID account: <https://orcid.org/0000-0002-2242-5638>
- 3- My Scopus account: <https://www.scopus.com/authid/detail.uri?authorId=56407153000>

(F) List of publication indexed in Web of Science

1. **S. A. Alsagaby**. Transcriptomics-Based Investigation of Molecular Mechanisms Underlying Apoptosis Induced by ZnO Nanoparticles in Human Diffuse Large B-Cell Lymphoma. *International Journal of Nanomedicine*, 2022;17:2261
2. **S. A. Alsagaby**. Investigating the impact of RNA integrity variation on the transcriptome of human leukemic cells. *3 Biotech*, 2022;12(8):1-12
3. **S. A. Alsagaby**. A comprehensive study on abnormalities associated with red blood cells in Saudi adult patients. *International Journal of Health Sciences*, 2022;16(1):30-41
4. **S. Alsagaby**, A. A. Ahmed, Z. Rasheed, S. A. Althwab, A. S. M. Aljohani, F. A. Alhumaydhi, H. T. Alhomaidan, A. S. Alkhamiss, M. Alkhowailed and A. Alaqeel. Association of genetic polymorphisms in DNA repair genes ERCC2 Asp312Asn (rs1799793), ERCC2 Lys 751 Gln (rs13181), XRCC1 Arg399 Gln (rs25487) and XRCC3 Thr 241Met (rs861539) with the susceptibility of lung cancer in Saudi population. *Nucleosides, Nucleotides & Nucleic Acids*, 2022;1-25
5. C. Yang, A. Alam, F. A. Alhumaydhi, M. S. Khan, **S. A. Alsagaby**, W. Al Abdulmonem, M. Hassan, A. Shamsi, B. Bano and D. K. Yadav. Bioactive Phytoconstituents as Potent Inhibitors of Tyrosine-Protein Kinase Yes (YES1): Implications in Anticancer Therapeutics. *Molecules*, 2022;27(10):3060
6. A. Shamsi, M. Shahwan, M. S. Khan, F. A. Alhumaydhi, **S. A. Alsagaby**, W. Al Abdulmonem, B. Abdullaev and D. K. Yadav. Mechanistic Insight into Binding of Huperzine A with Human Serum Albumin: Computational and Spectroscopic Approaches. *Molecules*, 2022;27(3):797
7. A. Shamsi, D. DasGupta, F. A. Alhumaydhi, M. S. Khan, **S. A. Alsagaby**, W. Al Abdulmonem, M. I. Hassan and D. K. Yadav. Inhibition of MARK4 by serotonin as an attractive therapeutic approach to combat Alzheimer's disease and neuroinflammation. *RSC Medicinal Chemistry*, 2022; 13:737-745
8. V. D. Seshadri, A. A. A. Oyouuni, W. M. Bawazir, **S. A. Alsagaby**, K. F. Alsharif, A. Albrakati and O. M. Al - Amer. Zingiberene exerts chemopreventive activity against 7, 12 - dimethylbenz (a) anthracene - induced breast cancer in Sprague - Dawley rats. *Journal of Biochemical and Molecular Toxicology*, 2022;e23146
9. Z. Rasheed, H. Alhomaidan, A. Shariq, M. Alkhowailed, F. Alqossayir, N. Rasheed, A. Alkhamiss, R. Alghsham, **Suliman A. Alsagaby**, A. Hershman and S. Alharbi. An Updated Analysis on the Risk Factors Associated with COVID-19 Transmission. *Open Access Macedonian Journal of Medical Sciences*, 2022;10(E):355-360
10. A. M. Mousa, F. A. Alhumaydhi, A. A. H. Abdellatif, W. A. Abdulmonem, M. S. Alkhowailed, **S. A. Alsagaby**, O. Al Rugaie, A. M. Alnuqaydan, A. S. M. Aljohani and M. Aljasir. Curcumin and ustekinumab cotherapy alleviates induced psoriasis in rats through their antioxidant, anti-inflammatory, and antiproliferative effects. *Cutaneous and Ocular Toxicology*, 2022;41(1):33-42
11. S. A. Mir, A. Firoz, M. Alaidarous, B. Alshehri, A. A. B. Dukhyil, S. Banawas, **S. A. Alsagaby**, W. Alturaiki, G. A. Bhat and F. Kashoo. Identification of SARS-CoV-2 RNA-dependent RNA polymerase inhibitors from the major phytochemicals of *Nigella sativa*: An in silico approach. *Saudi Journal of Biological Sciences*, 2022;29(1):394-401
12. N. Khare, S. K. Maheshwari, S. M. D. Rizvi, H. M. Albadrani, **S. A. Alsagaby**, W. Alturaiki, D. Iqbal, Q. Zia, C. Villa and S. K. Jha. Homology Modelling, Molecular Docking and Molecular Dynamics Simulation Studies of CALMH1 against Secondary Metabolites of *Bauhinia variegata* to Treat Alzheimer's Disease. *Brain Sciences*, 2022;12(6):770
13. M. S. Khan, M. Shahwan, A. Shamsi, F. A. Alhumaydhi, **S. A. Alsagaby**, W. Al Abdulmonem, B. Abdullaev and D. K. Yadav. Elucidating the Interactions of Fluoxetine with Human Transferrin Employing Spectroscopic, Calorimetric, and In Silico Approaches: Implications of a Potent Alzheimer's Drug. *ACS omega*, 2022;7(10):9015-9023
14. S. Jahan, U. A. Ansari, A. J. Siddiqui, D. Iqbal, J. Khan, S. Banawas, B. Alshehri, M. M. Alshahrani, **S. A. Alsagaby** and N. S. Redhu. Nobiletin Ameliorates Cellular Damage and Stress Response and Restores Neuronal Identity Altered by Sodium Arsenate Exposure in Human iPSCs-Derived hNPCs. *Pharmaceuticals*, 2022;15(5):593
15. **S. A. Alsagaby**. Molecular Insights into the Potential of Extracellular Vesicles Released from Mesenchymal Stem Cells and Other Cells in the Therapy of Hematologic Malignancies. *Stem Cells International*, 2021: 6633386.
17. S. Jabeen, A. U. Khan, W. Ahmed, S. A. Jafri, U. Bacha, A. Ali, H. S. Muzammil, **S. A. Alsagaby**, W. Al Abdulmonem and M. A. Abdelgawad. Disease specific symptoms indices in patients with celiac disease—A hardly recognised entity. *Frontiers in Nutrition*, 2022;9:944449.
18. D. Iqbal, S. M. D. Rizvi, M. T. Rehman, M. S. Khan, A. Bin Dukhyil, M. F. AlAjmi, B. M. Alshehri, S. Banawas, **S. A. Alsagaby**, Q. Zia and M. Alsaweed. Soyasapogenol-B as a Potential Multitarget Therapeutic Agent for Neurodegenerative Disorders: Molecular Docking and Dynamics Study. *Entropy*, 2022;24(5):593

19. M. Imran, M. Aslam, **S. A. Alsagaby**, F. Saeed, I. Ahmad, M. Afzaal, M. U. Arshad, M. A. Abdelgawad, A. H. El - Ghorab and A. Khames. Therapeutic application of carvacrol: A comprehensive review. *Food Science & Nutrition*, 2022;23: 2994
20. S. Bijani, D. Iqbal, S. Mirza, V. Jain, S. Jahan, M. Alsaweed, Y. Madkhali, **S. A. Alsagaby**, S. Banawas and A. Algarni. Green Synthesis and Anticancer Potential of 1, 4-Dihydropyridines-Based Triazole Derivatives: In Silico and In Vitro Study. *Life*, 2022;12(4):519
21. S. Anwar, D. DasGupta, A. Shafie, F. A. Alhumaydhi, **S. A. Alsagaby**, M. Shahwan, F. Anjum, W. Al Abdulmonem, S. E. Sharaf and M. I. Hassan. Implications of tempol in pyruvate dehydrogenase kinase 3 targeted anticancer therapeutics: Computational, spectroscopic, and calorimetric studies. *Journal of Molecular Liquids*, 2022;350:118581
22. S. Anwar, D. DasGupta, N. Azum, S. Y. M. Alfaifi, A. M. Asiri, F. A. Alhumaydhi, **S. A. Alsagaby**, S. E. Sharaf, M. Shahwan and M. I. Hassan. Inhibition of PDK3 by artemisinin, a repurposed antimalarial drug in cancer therapy. *Journal of Molecular Liquids*, 2022;355:118928
23. F. Anjum, M. N. Sulaimani, A. Shafie, T. Mohammad, G. M. Ashraf, A. L. Bilgrami, F. A. Alhumaydhi, **S. A. Alsagaby**, D. K. Yadav and M. I. Hassan. Bioactive phytoconstituents as potent inhibitors of casein kinase-2: dual implications in cancer and COVID-19 therapeutics. *RSC advances*, 2022;12(13):7872-7882
24. W. Alturaiki, A. Alhamad, M. Alturaiqy, S. A. Mir, D. Iqbal, A. A. Bin Dukhyil, M. Alaidarous, B. Alshehri, **S. A. Alsagaby** and S. G. Almalki. Assessment of IL - 1 β , IL - 6, TNF - α , IL - 8, and CCL 5 levels in newly diagnosed Saudi patients with rheumatoid arthritis. *International Journal of Rheumatic Diseases*, 2022;25(9):1013-1019
25. A. S. Alkhamiss, A. A. Ahmed, Z. Rasheed, R. Alghsham, A. Shariq, T. Alsaeed, S. A. Althwab, **S. Alsagaby**, A. S. M. Aljohani and F. A. Alhumaydhi. Mucormycosis co-infection in COVID-19 patients: An update. *Open Life Sciences*, 2022;17(1):917-937
26. N. K. Alharbi, J. A. Al-Tawfiq, A. Alwehaibe, M. W. Alenazi, A. Almasoud, A. Algaisi, F. A. Alhumaydhi, A. M. Hashem, M. Bosaeed and **S. A. Alsagaby**. Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines. *Infection and Drug Resistance*, 2022;15:4127
27. N. K. Alharbi, J. A. Al-Tawfiq, S. Alghnam, A. Alwehaibe, A. Alasmari, **S. A. Alsagaby**, F. Alsubaie, M. Alshomrani, F. M. Farahat and M. Bosaeed. Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi Arabia. *Journal of infection and public health*, 2022;15(5):573-577
28. M. Suresh, M. Alfonisan, W. Alturaiki, M. S. Al Aboody, F. A. Alfaiz, M. Premanathan, R. Vijayakumar, K. Umamageswari, S. Al Ghamdi and **S. A. Alsagaby**. Investigations of bioactivity of *Acalypha indica* (L.), *Centella asiatica* (L.) and *croton bonplandianus* (Baill) against multidrug resistant bacteria and cancer cells. *Journal of Herbal Medicine*, 2021;28:100359
29. A. Shamsi, M. Shahwan, F. A. Alhumaydhi, A. S. S. Alwashmi, M. A. Aljasir, **S. A. Alsagaby**, W. Al Abdulmonem, M. I. Hassan and A. Islam. Spectroscopic, calorimetric and in silico insight into the molecular interactions of Memantine with human transferrin: Implications of Alzheimer's drugs. *International Journal of Biological Macromolecules*, 2021;190:660-666
30. A. M. Mousa, A. Almatroudi, A. S. Alwashmi, W. Al Abdulmonem, A. S. M. Aljohani, F. A. Alhumaydhi, M. A. Alsahli, F. Alrumaihi, **S. A. Alsagaby**, K. S. Allemailem and A. A. H. Abdellatif. Thyme oil alleviates Ova-induced bronchial asthma through modulating Th2 cytokines, IgE, TSLP and ROS. *Biomedicine & Pharmacotherapy*, 2021;140:111726
31. M. M. Khodeir, H. A. Shabana, Z. Rasheed, A. S. Alkhamiss, M. Khodeir, M. S. Alkhowailed, S. Alharbi, M. Alsoghair, **S. A. Alsagaby** and W. Al Abdulmonem. COVID-19: Post-recovery long-term symptoms among patients in Saudi Arabia. *PloS one*, 2021;16(12):e0260259
32. M. M. Khodeir, H. A. Shabana, A. S. Alkhamiss, Z. Rasheed, M. Alsoghair, **S. A. Alsagaby**, M. I. Khan, N. Fernandez and W. Al Abdulmonem. Early prediction keys for COVID-19 cases progression: A meta-analysis. *Journal of infection and public health*, 2021;14(5):561-569
33. D. Iqbal, M. S. Khan, M. Waiz, M. T. Rehman, M. Alaidarous, A. Jamal, A. S. Alothaim, M. F. AlAjmi, **S. A. Alsagaby**, B. M. Alshehri and S. Banawas. Exploring the Binding Pattern of Geraniol with Acetylcholinesterase through In Silico Docking, Molecular Dynamics Simulation, and In Vitro Enzyme Inhibition Kinetics Studies. *Cells*, 2021;10(12):3533
34. S. Hala, P. Ribeca, H. A. Aljami, **S. A. Alsagaby**, I. Qasim, S. C. Gilbert and N. K. Alharbi. Transcriptomic Profiling of Dromedary Camels Immunised with a MERS Vaccine Candidate. *Veterinary sciences*, 2021;8(8):156
35. M. M. Fareed, M. A. El-Esawi, E. M. El-Ballat, G. E.-S. Batiha, A. Rauf, F. M. El-Demerdash, F. A. Alhumaydhi and **S. A. Alsagaby**. In Silico Drug Screening Analysis against the Overexpression of PGAM1 Gene in Different Cancer Treatments. *BioMed Research International*, 2021; 5515692

36. W. Alturaiki, A. Mubarak, S. A. Mir, A. Afridi, M. Premanathan, S. Mickymaray, R. Vijayakumar, **S. A. Alsagaby**, S. G. Almalki and F. Alghofaili. Plasma levels of BAFF and APRIL are elevated in patients with asthma in Saudi Arabia. *Saudi Journal of Biological Sciences*, 2021;28(12):7455-7459
37. S. A. Althwab, A. A. Ahmed, Z. Rasheed, M. Alkhowailed, A. Hershan, **S. Alsagaby**, M. A. Alblihed, A. Alaqeel, J. Alrehaili and F. A. Alhumaydhi. ATP2B1 genotypes rs2070759 and rs2681472 polymorphisms and risk of hypertension in Saudi population. *Nucleosides, Nucleotides & Nucleic Acids*, 2021;40(11):1075-1089
38. **S. A. Alsagaby**, I. A. Brewis, R. Vijayakumar, F. A. Alhumaydhi, A. S. Alwashmi, N. K. Alharbi, W. Al Abdulmonem, M. Premanathan, G. Pratt and C. Fegan. Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia. *Electronic Journal of Biotechnology*, 2021;52:1-12
39. **S. A. Alsagaby**, A. Aljouie, T. H. Alshammari, S. A. Mir, F. A. Alhumaydhi, W. Al Abdulmonem, H. Alshaalan, H. Alomaish, R. Daghistani and A. Alsehawi. Haematological and radiological-based prognostic markers of COVID-19. *Journal of Infection and Public Health*, 2021;14(11):1650-1657
40. **S. A. Alsagaby** and M. T. Alharbi. Cancer in Saudi Arabia (CSA): Web-Based Application to Study Cancer Data Among Saudis Using Waterfall Model. *Journal of Multidisciplinary Healthcare*, 2021;14:2333
42. F. A. Alhumaydhi, A. M. H. Mackawy, E. N. Morgan, W. Al Abdulmonem, **S. A. Alsagaby**, A. S. S. Alwashmi, A. S. M. Aljohani, M. A. Aljasir, S. A. Almatroodi and A. M. Alruwetei. Potential role of folic acid in preventing male infertility associated with MTHFR gene C677T (rs1801133) polymorphism. *All Life*, 2021;14(1):730-743
43. F. A. Alhumaydhi, M. A. Aljasir, A. S. M. Aljohani, **S. A. Alsagaby**, A. S. S. Alwashmi, M. Shahwan, M. I. Hassan, A. Islam and A. Shamsi. Probing the interaction of memantine, an important Alzheimer's drug, with human serum albumin: In silico and in vitro approach. *Journal of Molecular Liquids*, 2021;340:116888
44. R. S. Al-Baradie, S. Pu, D. Liu, Y. Zeinolabediny, G. Ferris, C. Sanfeli, R. Corpas, E. Garcia-Lara, **S. A. Alsagaby** and B. M. Alshehri. Monomeric C-reactive protein localized in the cerebral tissue of damaged vascular brain regions is associated with neuro-inflammation and neurodegeneration-an immunohistochemical study. *Frontiers in Immunology*, 2021;12:644213
45. W. Al Abdulmonem, Z. Rasheed, **S. A. Alsagaby**, A. S. M. Aljohani, A. S. Alkhamiss and A. A. Ahmed. Impact of ERCC2 Lys751Gln (rs13181), ERCC2 Asp312Asn (rs1799793) and XRCC1 Arg399Gln (rs25487) polymorphisms on the risk of prostate cancer among cases from the central region of Saudi Arabia. *Gene Reports*, 2021;24:101278
46. S. Abbas, D. Chang, N. Riaz, A. A. Maan, M. K. I. Khan, I. Ahmad, **S. A. Alsagaby**, A. El-Ghorab, M. Ali and M. Imran. In-vitro stress stability, digestibility and bioaccessibility of curcumin-loaded polymeric nanocapsules. *Journal of Experimental Nanoscience*, 2021;16(1):229-245
47. M. A. A. Radwan, F. M. Alminderej, M. Premanathan, A. S. S. Alwashmi, F. A. Alhumaydhi, W. Alturaiki and **S. A. Alsagaby**. Synthesis and evaluation of novel isoindoline-1, 3-dione derivatives as anticancer agents. *Russian Journal of Bioorganic Chemistry*, 2020;46(6):1087-1098
48. F. A. Alzahrani, F. Ahmed, M. Sharma, M. Rehan, M. Mahfuz, M. N. Baeshen, Y. Hawsawi, A. Almatrafi, **S. A. Alsagaby** and M. A. Kamal. Investigating the pathogenic SNPs in BLM helicase and their biological consequences by computational approach. *Scientific reports*, 2020;10(1):1-22
49. **S. A. Alsagaby**, R. Vijayakumar, M. Premanathan, S. Mickymaray, W. Alturaiki, R. S. Al-Baradie, S. AlGhamdi, M. A. Aziz, F. A. Alhumaydhi and F. A. Alzahrani. Transcriptomics-based characterization of the toxicity of ZnO nanoparticles against chronic myeloid leukemia cells. *International Journal of Nanomedicine*, 2020;15:7901
50. T. A. Aljasim, A. Almasoud, H. A. Aljami, M. W. Alenazi, **S. A. Alsagaby**, A. N. Alsaleh and N. K. Alharbi. High rate of circulating MERS-CoV in Dromedary camels at slaughterhouses in Riyadh, 2019. *Viruses*, 2020;12(11):1215
51. Y. Ke, M. S. Al Aboody, W. Alturaiki, **S. A. Alsagaby**, F. A. Alfaiz, V. P. Veeraraghavan and S. Mickymaray. Photosynthesized gold nanoparticles from *Catharanthus roseus* induces caspase-mediated apoptosis in cervical cancer cells (HeLa). *Artificial cells, nanomedicine, and biotechnology*, 2019;47(1):1938-1946
52. R. S. Baradie, A. M. Alghohary, E. S. Al-Malki, Y. H. S. Babair, A. M. Alsulaiman and **S. A. Alsagaby**. Can pharmacological inhibitors and antibodies against m CRP suppress interactions with platelets and leukocytes-dampening inflammation after stroke. *Bio. Medical J Sci Tech Res*, 2019;13084-9
53. **S. A. Alsagaby** and F. A. Alhumaydhi. Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia. *Saudi medical journal*, 2019;40(4):317
54. **S. A. Alsagaby**. Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia. *Oncology Reviews*, 2019;13:149-158.
55. **S. A. Alsagaby**. Understanding the fundamentals of proteomics. *Current Topics in Protein and Peptide Research*, 2019;20(1):25 -33
56. **S. A. Alsagaby**. Transcriptomics-based validation of the relatedness of heterogeneous nuclear ribonucleoproteins to chronic lymphocytic leukemia as potential biomarkers of the disease aggressiveness. *Saudi Medical Journal*, 2019;40(4):328-337

57. R. Vijayakumar, T. Sandle, M. S. Al-Aboody, M. K. AlFonaisan, W. Alturaiki, S. Mickymaray, M. Premanathan and **S. A. Alsagaby**. Distribution of biocide resistant genes and biocides susceptibility in multidrug-resistant *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Acinetobacter baumannii*—A first report from the Kingdom of Saudi Arabia. *Journal of Infection and Public Health*, 2018;11(6):812-816
58. S. Mickymaray, W. Alturaiki, M. S. Al-Aboody, P. Mariappan, V. Rajenderan, **S. A. Alsagaby**, U. Kalyanasundram and A. A. Alarfajj. Anti-bacterial efficacy of bacteriocin produced by marine *Bacillus subtilis* against clinically important extended spectrum beta-lactamase strains and methicillin-resistant *Staphylococcus aureus*. *International Journal of Medical Research & Health Sciences*, 2018;7(2):75-83
59. R. Vijayakumar, M. S. Al-Aboody, W. Alturaiki, S. A. Alsagaby and S. Tim. A study of airborne fungal allergens in sandstorm dust in Al-Zulfi, central region of Saudi Arabia. *Journal of Environmental and Occupational Health*, 2017;6(1):27-33
60. **S. A. Alsagaby**, P. Brennan and C. Pepper. Key molecular drivers of chronic lymphocytic leukemia. *Clinical Lymphoma Myeloma and Leukemia*, 2016;16(11):593-606
61. K. Govindaraju, K. Krishnamoorthy, **S. A. Alsagaby**, G. Singaravelu and M. Premanathan. Green synthesis of silver nanoparticles for selective toxicity towards cancer cells. *IET nanobiotechnology*, 2015;9(6):325-330
63. **S. A. Alsagaby**, S. Khanna, K. W. Hart, G. Pratt, C. Fegan, C. Pepper, I. A. Brewis and P. Brennan. Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia. *Journal of proteome research*, 2014;13(11):5051-5062

(G) Scientific Research -Related Awards

- 1- I was awarded the Key Scientific Article Certificate of 2015 from the Institute of Global Medical Discovery in Canada in recognition of the research article titled “Proteomics-Based Strategies to Identify Proteins Relevant to Chronic Lymphocytic Leukaemia” that was published in the Journal of Proteome Research.

- 2- I was awarded the IET Nanobiotechnology Premium Award of 2017 from the Institution of Engineering and Technology in the UK in recognition of the research article titled “Green synthesis of silver nanoparticles for selective toxicity towards cancer cells” that was published in the Journal of IET Nanobiotechnology.

Skills

(A) Leadership

As a vice-dean of quality and development I worked with the team that prepared the College of Sciences to successfully receive the German academic accreditation ASIIN. Later I was selected to be a vice-dean of postgraduate studies and scientific research in the College where I play leadership roles to create a motivating environment for the faculty members to conduct scientific research. This resulted in number of achievements:

1. Establishment of various research labs; in particular the Central Biomedical Science Research Labs (CBRLs).
2. Creating research groups like the Molecular Cancer Research Group (MCRG) and Infection/Immunity Research Group (IIRG).
3. Organizing Scientific Conferences, such as Molecular Medicine Research Day (2015), Cancer Research Day (2017) and Asthma Research Day (2017).
4. Receiving research grants from funding bodies.
5. Running weekly scientific seminars in the different departments of the college.

(B) Team working

Creating a motivating environment for scientific research was my first priority since I worked in the college as an assistant professor. Achieving this goal required team working as well as leadership skills. For example, beside the leadership roles I played to establish CBRLs I have been working side by side with other assistant professors to develop CBRLs. The development processes passed through series of stages including making a list of required instruments/tools and

materials, search for reliable manufacturers and local distributors, supervising instruments installation, receiving training, developing workflows, writing standard operating procedures (SOPs), writing stock inventory and making instrument documentation system for usage and maintenance history.

In addition to my role as a leader of the MCRG, I and other members of the research group employ team-working skills to formulate hypotheses, design projects, write research proposals, conduct lab work, write manuscripts, submit manuscripts to journals and present our findings in conferences.

(C) Communication and Networking

Having good communication skills helped me to communicate well with Arabic and non-Arabic faculty members. This has been essential to encourage the faculty members to apply for research grants and conduct high quality research projects. Employing good networking skills assisted me as a head of CBRLs and leader of MCRG to seek collaboration outside the College. This successfully led to building good relationships/collaborations with different universities, hospitals and research centres like Qassim University, King Fahd Medical City – Oncology Centre, Prince Sultan Military Medical City – Oncology Department, King Faisal Specialized Hospital Research Centre – Proteomics Unit, King Saud University – Stem Cell Research Centre, and King Abdullah International Medical Research Centre.

(D) Problem Solving

Having Problem solving skills facilitated overcoming many obstacles in the way of developing a nurturing research environment in the College. In the context of CBRLs, I have been heavily participating in solving problems that range from sorting out infrastructure issues to troubleshooting experimental workflow and instrumental performance, in particular proteomics, transcriptomics and flow-cytometry.

Research Interest

I am interested in conducting research concerning molecular medicine and biochemistry of different diseases including cancer, neurodegenerative diseases and microbial infections for discovery of therapeutic targets and biomarkers. Advanced molecular biology approaches like proteomics, transcriptomics, genomics and epigenomics are my first interest that I have been utilizing in my research.